Innate Pharma S.A. ADS (IPHA) is a publicly traded Healthcare sector company. As of August 19, 2026, IPHA trades at $2.12 with a market cap of $194.38M and a P/E ratio of 0.00. IPHA moved +2.42% today. Year to date, IPHA is +21.14%; over the trailing twelve months it is -5.15%. Its 52-week range spans $1.17 to $2.71. Analyst consensus is strong buy with an average price target of $6.67. Rallies surfaces IPHA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for IPHA, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $2.12 |
| Market Cap | $194.38M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.71 |
| 52-Week Low | $1.17 |
| Volume | 24.62K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover IPHA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.67.